Trials / Completed
CompletedNCT00422175
Single Dose Study to Assess the Safety, Tolerability, Concentration in Body and Effect of BAF312
A First-in-Human Study for BAF312: A Two Parts, Single Center, Randomized, Double-Blind, Placebo-Controlled Ascending Single Dose Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral BAF312 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 63 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety, tolerability, and effect of oral BAF312 on bodily functions as well as the body's absorption, distribution, metabolism, and excretion of BAF312 in healthy volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BAF 312 |
Timeline
- Start date
- 2006-10-01
- Completion
- 2007-11-01
- First posted
- 2007-01-15
- Last updated
- 2007-11-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00422175. Inclusion in this directory is not an endorsement.